ARTICLES|ONLINE FIRST Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial Ingrid M Bistervels, Andrea Buchmüller, Hanke M G Wiegers, et al Lancet Published:October 28, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)02128-6 Summary Background Pregnancy-related venous thromboembolism is a leading...

ARTICLES|ONLINE FIRST Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial Pengfei Yang, Lili Song, Yongwei Zhang, et al Lancet Published:October 27, 2022 DOI: https://doi.org/10.1016/S0140-6736(22)01882-7 Summary Background The optimum systolic blood pressure after endovascular thrombectomy for acute ischaemic stroke is unc...

Long vs Short Duration Antibiotic Therapy for VAP Ventilator-associated pneumonia (VAP) is a major cause of morbidity and mortality in the ICU. It accounts for nearly 25% of infections in ICU patients. While there are guidelines to treat VAP, uncertainties remain when treating VAP due to Pseudomonas aeruginosa (PA-VAP), and the optimal duration of antibiotic therapy continues to be debated. In addition, there is limited evidence regarding the recurrence r...

ARTICLES| VOLUME 400, ISSUE 10359, P1213-1222, OCTOBER 08, 2022 Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study Carlos K H Wong, Ivan C H Au, Kristy T K Lau, et al Lancet 2022; 400: 1213-1222 Published:October 08, 2022 D...

Research Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study Junyi Wang, Joshua J Gagne, Sushama Kattinakere-Sreedhara, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2021-069931 (Published 04 October 2022)Cite this as: BMJ 2022;379:e069931 Abstract Objective To evaluate the association between initiation of fluoroquinolones and hospital admission o...

Effect of Prone Position C-ARDS COVID-19 has resulted in the death of over 4 million people worldwide. In severe cases of COVID-19, acute respiratory infection leads to severe pneumonia, which worries to progress hypoxaemia and acute respiratory distress syndrome (ARDS).  Prolonged sessions in the prone position is an effective intervention to decrease mortality in these patients. It has been adopted for the treatment of C-ARDS, both before intubation and d...

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al Lancet Infect Dis 2022; 22: 1444-1454 Summary Background There is an unmet need for COVID-19 prevention in patient populations who have not mounted or are not expected to mount an adequate immune response to complete C...

ARTICLES| VOLUME 22, ISSUE 10, P1435-1443, OCTOBER 01, 2022 Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study Martina E McMenamin, Joshua Nealon, Yun Lin, et al Lancet Infect Dis 2022; 22: 1435-1443 Summary Background Hong Kong maintained low circulation of SARS-CoV-2 until a major community epidemic of the omicron (B.1.1.529) sublineage BA.2 b...

Continuous Monitoring of Patients Using Wearable Technology Vital sign deterioration may be preventable if strategies are used to identify patients at a higher risk. Early Warning Score (EWS) systems were developed many years ago to identify patients at risk of clinical deterioration using physiological parameter-based protocols. Since then, many hospitals have adopted periodic vital sign monitoring protocols which mandate a stepwise increase in vital sign measurem...

ORIGINAL ARTICLEFREE PREVIEW Trial of Intravenous Immune Globulin in Dermatomyositis Rohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, et al N Engl J Med 2022; 387:1264-1278DOI: 10.1056/NEJMoa2117912 Abstract BACKGROUND Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. METHODS We conducted a randomized, placebo-controlled trial involving patients with active dermatomyositis. The p...